Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis

Rheumatology (United Kingdom)

Volumn 55, Issue 1, 2016, Pages 115-119

  Raja, Jasmin ^a,b   Nihtyanova, Svetlana I ^a   Murray, Charles D ^c   Denton, Christopher P ^a   Ong, Voon H ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

gastrointestinal manifestation; intravenous immunoglobulin; myositis; refractory; systemic sclerosis

Indexed keywords

CREATINE KINASE; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; MUSCLE STRENGTH; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; TREATMENT DURATION;

EID: 84960082941     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev318     Document Type: Article

References (20)

1. Poelman CL, Hummers LK, Wigley FM et al. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. J Rheumatol 2015;42:236-42.
2. Takehara K, Ihn H, Sato S. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol 2013;31(2 Suppl 76):151-6.
3. Wang DX, Shu XM, Tian XL et al. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review. Clin Rheumatol 2012;31:801-6.
4. Qi M, Schifferli JA. Inhibition of complement activation by intravenous immunoglobulins. Arthritis Rheum 1995;38:146.
5. Amran D, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994;73:180-6.
6. Molina V, Blank M, Shoenfeld Y. Intravenous immunoglobulin and fibrosis. Clin Rev Allergy Immunol 2005;29:321-6.
7. Clark K, Etomi O, Denton CP, Ong VH, Murray C. Intravenous immunoglobulin therapy for severe gastrointestinal involvement in systemic sclerosis-case report. Clinical and Experimental Rheumatology 2015;33:1-3.
8. van den Hoogen F, Khanna D, Fransen J et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-55.
9. Shaw M, Dent J, Beebe T et al. The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials. Health Qual Life Outcomes 2008;6:31.
10. Khanna D, Hays RD, Maranian P et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009;61:1257-63.
11. Zuber-Jerger I, Muller A, Kullmann F et al. Gastrointestinal manifestation of systemic sclerosis-thickening of the upper gastrointestinal wall detected by endoscopic ultrasound is a valid sign. Rheumatology 2010;49:368-72.
12. Roberts CG, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM. A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut 2006;55:1697-703.
13. Manetti M, Neumann E, Milia AF et al. Severe fibrosis and increased expression of fibrogenic cytokines in the gastric wall of systemic sclerosis patients. Arthritis Rheum 2007;56:3442-7.
14. Dzeing-Ella AB, Ranque A, Authier B et al. Intravenous immunoglobulin (IVIg) in the treatment of systemic sclerosis (SSc) associated myopathy [abstract]. Arthritis Rheum 2010;62(Suppl 10):576.
15. Asano Y, Ihn H, Asashima N et al. A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. Rheumatology 2005;44:824 B 6.
16. McGaha T, Saito S, Phelps RG et al. Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4Rα and transforming growth factor-β genes. J Invest Dermatol 2001;116:136-43.
17. Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor β receptors. Arthritis Rheum 2001;44:474-80.
18. Blank M, Levy Y, Amital H et al. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum 2002;46:1689-90.
19. Kawaguchi Y, Nakamura Y, Matsumoto I et al. Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility. Ann Rheum Dis 2009;68:710-4.
20. Singh J, Mehendiratta V, Del Galdo F et al. Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells. Am J Physiol Gastrointest Liver Physiol 2009;297:G1206-13.